1. Home
  2. NGG vs VRTX Comparison

NGG vs VRTX Comparison

Compare NGG & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National Grid Transco PLC National Grid PLC (NEW)

NGG

National Grid Transco PLC National Grid PLC (NEW)

HOLD

Current Price

$90.45

Market Cap

85.7B

Sector

Utilities

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$465.81

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGG
VRTX
Founded
1990
1989
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
EDP Services
Sector
Utilities
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
85.7B
115.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
NGG
VRTX
Price
$90.45
$465.81
Analyst Decision
Hold
Buy
Analyst Count
2
28
Target Price
N/A
$537.64
AVG Volume (30 Days)
1.2M
1.1M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
3.40%
N/A
EPS Growth
N/A
836.54
EPS
N/A
15.32
Revenue
N/A
$2,488,652,000.00
Revenue This Year
N/A
$10.79
Revenue Next Year
$10.73
$10.14
P/E Ratio
$115.91
$30.67
Revenue Growth
N/A
46.20
52 Week Low
$62.76
$362.50
52 Week High
$94.64
$516.50

Technical Indicators

Market Signals
Indicator
NGG
VRTX
Relative Strength Index (RSI) 54.70 46.10
Support Level $89.14 $453.97
Resistance Level $94.64 $473.78
Average True Range (ATR) 1.47 16.32
MACD -0.50 -1.80
Stochastic Oscillator 30.10 25.38

Price Performance

Historical Comparison
NGG
VRTX

About NGG National Grid Transco PLC National Grid PLC (NEW)

National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission and electricity generation in the United States, metering services, merchant transmission lines in the UK, and the Grain (UK) liquefied natural gas facility.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: